{
  "docId": "019de517-75a1-7387-968b-d0dc513bf421",
  "docSlug": "e930bfcc8684afb6f5a4dd5442b5166d",
  "documentTitle": "Ocuphire Pharma | Investor Presentation Deck | 42 slides",
  "authorId": "ocuphire-pharma",
  "authorName": "Ocuphire Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 42,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de517-75a1-7387-968b-d0dc513bf421/16",
  "deckHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421",
  "deckJsonHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421.json",
  "deckAnchorHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.699,
        "w": 0.36,
        "x": 0.599,
        "y": 0.21
      },
      "kind": "diagram",
      "text": "Mechanism of Action - Ref-1 Inhibition\nHypoxia -> Ref-1 -> HIF-1α -> VEGF (Signaling Cascade)\nInflammation -> Ref-1 -> NF-κB -> TNF-α Chemokines -> Other Growth Factors (Signaling Cascade)\nAPX3330 inhibits Ref-1\nAnti-VEGF and Steroids target Neovascularization",
      "attrs": {},
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e82d073e-afbf-47af-b8c3-52c9c1094084",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.029,
        "w": 0.09,
        "x": 0.049,
        "y": 0.94
      },
      "kind": "image",
      "text": "Ocuphire",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9cd6875c-4caa-45bc-82ee-3907b1038127",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.042,
        "w": 0.331,
        "x": 0.092,
        "y": 0.75
      },
      "kind": "list",
      "text": "Anti-VEGF injections do not target inflammation",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c5c2464-b69f-4ddd-bb3f-e7e80adbd39c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.331,
        "x": 0.092,
        "y": 0.599
      },
      "kind": "list",
      "text": "APX3330 does not deplete the VEGF levels but rather normalizes VEGF levels to physiologic levels",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9fe635ed-f549-4408-aebf-7f8e29d41a4e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.042,
        "w": 0.363,
        "x": 0.06,
        "y": 0.499
      },
      "kind": "list",
      "text": "Unique MOA decreases abnormal angiogenesis and inflammation",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac93f09f-bda4-47d4-a355-9d6ebbd3a9d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.199,
        "w": 0.34,
        "x": 0.083,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "Ref-1 (reduction-oxidation effector factor-1)\nA novel target for retinal diseases, is a transcription factor regulator of angiogenesis (VEGF) and inflammation (NFkB)",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73403f59-fde9-496f-8580-5197aec060ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.013,
        "w": 0.239,
        "x": 0.138,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Logsdon et al (2018), Li et al (2014).",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87304f33-fefd-4bc5-ba1f-33206394d151",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.889,
        "x": 0.049,
        "y": 0.054
      },
      "kind": "title",
      "text": "APX3330 - Mechanism of Action Targeting Ref-1 Inhibition",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef5882b3-18f3-4ece-8e80-325b33d74def",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.018,
        "w": 0.846,
        "x": 0.05,
        "y": 0.09
      },
      "kind": "title",
      "text": "Ref-1 Involved in Key Pathways that Contribute to Diabetic Retinopathy and Diabetic Macular Edema",
      "attrs": {},
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca95bfa5-6989-41a1-ae01-fb3f29907631",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 11,
      "beatId": "658ab0ae-6284-4b3b-b67a-e6c8bfbdd666",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Slides 11-16 present APX3330 as a solution for Diabetic Retinopathy",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 18,
      "from": 16,
      "name": "Aha Moment",
      "slug": "03-aha-moment",
      "bestFor": "Data-heavy sections, research findings, analytical arguments",
      "matchId": "06b3bd6b-dd7a-4246-9ad5-76e883655757",
      "evidence": "Slides 16-18 highlight APX3330's mechanism of action and in-vitro validation",
      "position": 0,
      "objective": "What makes APX3330 unique?",
      "structure": "The Problem/Question -> What the Data Shows -> The Insight",
      "confidence": 0.7,
      "description": "Establish a tension, present data, then deliver the insight that changes everything"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}